ArticleFrontiers in neuroscience2026
MOMHCA-SG: a multi-head cross-attention and similar graph convolutional network framework for Alzheimer's disease cell type classification.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is a complex neurodegenerative disorder with di-verse cellular and molecular characteristics. Due to its heterogeneous nature, early detection and understanding of AD are challenging, and conventional unimodal approaches often fail to capture the intricate interactions across different biological layers. Methods: We propose MOMHCA-SG, a novel multi-omics integration framework that combines a multi-head cross-attention mechanism (MHCA) with a graph convolutional network (GCN) guided by similarity network fusion (SNF). The framework first employs an autoencoder (AE) for dimensionality reduction and feature extraction, followed by MHCA to model inter-omic dependencies. A contrastive learning strategy is then utilized to refine latent representations, while the GCN performs final cell-type classification using fused similarity networks derived from both scRNA-seq and scATAC-seq datasets related to AD. Results: Extensive experiments on publicly available AD datasets demonstrate that MOMHCA-SG attains superior performance in both integration and classification tasks, achieving an ARI of 0.99, NMI of 0.98, and AMI of 0.98, with classification accuracy exceeding 0.98. Downstream bioinformatics analyses further identify key genes and signaling pathways potentially involved in AD pathogenesis, supporting the framework's biological interpretability. Discussion: MOMHCA-SG effectively preserves feature integrity during high-dimensional processing, dynamically integrates heterogeneous omics data, and captures cross-modality relationships. These capabilities highlight its potential as a powerful tool for elucidating disease mechanisms and advancing precision medicine in neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.